Director Hudson exercises options in Supernus (NASDAQ: SUPN) stock

Rhea-AI Filing Summary

Supernus Pharmaceuticals director Hudson Frederick M. reported an option exercise and share acquisition. On January 9, 2026, he exercised a director stock option to buy 15,000 shares of common stock at an exercise price of $12.98 per share. The corresponding derivative position, a director stock option granted on March 1, 2017 and expiring on March 1, 2026, was reduced by 15,000 options to 0 following the transaction.

As a result of this option exercise, Hudson Frederick M. now directly owns 61,307 shares of Supernus Pharmaceuticals common stock. The filing classifies all reported holdings as directly owned, with no indirect ownership structures noted in the data provided.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hudson Frederick M.

(Last) (First) (Middle)

C/O SUPERNUS PHARMACEUTICALS, INC.,

9715 KEY WEST AVENUE

(Street)

ROCKVILLE MD 20850

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SUPERNUS PHARMACEUTICALS, INC. [ SUPN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/09/2026		M		15,000	A	$12.98	61,307	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	$12.98	01/09/2026		M			15,000	03/01/2017	03/01/2026	Common Stock	15,000	$0	0	D

Explanation of Responses:

Remarks:

	/s/ Timothy C. Dec, as attorney-in-fact	01/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did SUPN director Hudson Frederick M. report?

Director Hudson Frederick M. reported exercising a director stock option for 15,000 shares of Supernus Pharmaceuticals common stock on January 9, 2026.

How many Supernus (SUPN) shares did the director acquire and at what price?

He acquired 15,000 shares of Supernus common stock at an exercise price of $12.98 per share through the option exercise.

How many Supernus (SUPN) shares does the director own after this transaction?

Following the reported transaction, Hudson Frederick M. directly owns 61,307 shares of Supernus Pharmaceuticals common stock.

What happened to the director’s stock options in this SUPN Form 4 filing?

A director stock option granted on March 1, 2017 with an exercise price of $12.98 and expiring on March 1, 2026 was exercised for 15,000 options, leaving 0 options remaining.

Is the ownership reported by the SUPN director direct or indirect?

The Form 4 data show the holdings as direct ownership (D), with no nature of indirect beneficial ownership indicated.

What transaction code is used in this Supernus (SUPN) insider filing?

The filing uses transaction code M, indicating the exercise or conversion of a derivative security, here a director stock option, into common stock.